Trial Profile
A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 26 Sep 2016 Status changed from recruiting to completed.
- 25 Aug 2015 According to an Allergan media release, pooled data from phase II/III studies will be presented at the 28th European College of Neuropsychopharmacology (ECNP) annual congress.
- 26 Jun 2012 New trial record